Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Splitomicin SCHEMBL2544804 | 1.00 | SIRT1 (1.00) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL13893535 | 0.90 | SIRT1 (0.81) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL14677465 | 0.84 | SIRT1 (0.72) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL13893534 | 0.79 | KDM4E (0.65) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL9121753 | 0.78 | HPGD (0.64) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL9123291 | 0.78 | HPGD (0.64) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL8313602 | 0.75 | KDM4E (0.60) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL30522627 | 0.75 | KDM4E (0.60) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL414928 | 0.75 | HSD17B10 (0.59) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL29688038 | 0.75 | HSD17B10 (0.59) | SIRT1KDM4ECYP1A2GLACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-20220280656-A1 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE | YALE UNIVERSITY | 2022-09-08 | — | — | US | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4715066-A1 | PANEL OF MICRORNAS AS BIOMARKERS OF NON-SEGMENTAL VITILIGO | Servicio Andaluz De Salud (ES) | 2026-03-25 | — | — | EP | disclosed |
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250281445-A1 | Method of dietary treatment for genetic and epigenetic diseases and disorders | OTT DAVID MICHAEL (US) | 2025-09-11 | — | — | US | disclosed |
| US-12338198-B2 | Cancer cell growth inhibiting composition and processed food | Hagihara Farm Production Institute Co., Ltd. (JP) | 2025-06-24 | — | — | US | disclosed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | disclosed |
| US-20220280656-A1 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE | YALE UNIVERSITY | 2022-09-08 | — | — | US | disclosed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| WO-2022115581-A1 | METHODS FOR TREATING INFERTILITY AND/OR ENDOMETRIOSIS COMPRISING EX-527 | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220135514-A1 | CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD | Hagihara Farm Production Institute Co., Ltd. (JP) | 2022-05-05 | — | — | US | disclosed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | SIRT1 4028/4885KDM4E 127/4885CYP1A2 4732/4885 |
| US-12338198-B2 | Cancer cell growth inhibiting composition and processed food | MKI67, FLOT1, VHL | SIRT1 4483/4885KDM4E 3370/4885CYP1A2 3310/4885 |
| US-20220280656-A1 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE | HBB, HBG1, HBZ | SIRT1 4760/4885KDM4E 4884/4885CYP1A2 4657/4885 |
| US-20220135514-A1 | CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD | MKI67, FLOT1, VHL | SIRT1 4382/4885KDM4E 3595/4885CYP1A2 2795/4885 |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | HBB, HBG1, HBZ | SIRT1 4760/4885KDM4E 4884/4885CYP1A2 4657/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | SIRT1 4028/4885KDM4E 127/4885CYP1A2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.